|
|
???tair.name??? >
???browser.page.title.author???
|
"tanasanvimon s"???jsp.browse.items-by-author.description???
Showing items 1-8 of 8 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國家衛生研究院 |
2023-09-25 |
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
|
Oh, DY;He, AR;Qin, SK;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, H;Bouattour, M;Tanasanvimon, S;McNamara, MG;Zaucha, R;Avallone, A;Tan, BJM;Cundom, J;Lee, CK;Takahashi, H;Ikeda, M;Chen, JS;Wang, JL;Makowsky, M;Rokutanda, N;Zotkiewicz, M;Kurland, JF;Cohen, G;Valle, JW |
| 國家衛生研究院 |
2023-05-24 |
Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer
|
Yoshino, T;Cervantes, A;Bando, H;Martinelli, E;Oki, E;Xu, RH;Mulansari, NA;Govind Babu, K;Lee, MA;Tan, CK;Cornelio, G;Chong, DQ;Chen, LT;Tanasanvimon, S;Prasongsook, N;Yeh, KH;Chua, C;Sacdalan, MD;Sow Jenson, WJ;Kim, ST;Chacko, RT;Syaiful, RA;Zhang, SZ;Curigliano, G;Mishima, S;Nakamura, Y;Ebi, H;Sunakawa, Y;Takahashi, M;Baba, E;Peters, S;Ishioka, C;Pentheroudakis, G |
| 國立成功大學 |
2023 |
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
|
Oh, D.-Y.;He, A.R.;Qin, S.;Chen, L.-T.;Okusaka, T.;Vogel, A.;Kim, J.W.;Suksombooncharoen, T.;Lee, M.A.;Kitano, M.;Burris, H.;Bouattour, M.;Tanasanvimon, S.;McNamara, McNamara M.G.;Zaucha, R.;Avallone, Avallone A.;Tan, B.;Cundom, J.;Lee, C.-K.;Takahashi, H.;Ikeda, M.;Chen, J.-S.;Wang, J.;Makowsky, Makowsky M.;Rokutanda, N.;Żotkiewicz, M.;Kurland, J.F.;Cohen, G.;Valle, J.W. |
| 國家衛生研究院 |
2022-11 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Lee, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Zotkiewicz, M;Cohen, G;Valle, JW |
| 國家衛生研究院 |
2022-09 |
Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, RE;Avallone, A;Cundom, JE;Rokutanda, N;Watras, M;Cohen, G;Valle, JW |
| 國家衛生研究院 |
2022-02-01 |
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1
|
Oh, DY;He, AR;Qin, S;Chen, LT;Okusaka, T;Vogel, A;Kim, JW;Suksombooncharoen, T;Lee, MA;Kitano, M;Burris, HA;Bouattour, M;Tanasanvimon, S;Zaucha, R;Avallone, A;Cundom, J;Rokutanda, N;Xiong, J;Cohen, G;Valle, JW |
| 國立成功大學 |
2021 |
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
|
Even, C.;Wang, H.-M.;Li, S.-H.;Ngan, R.K.-C.;Dechaphunkul, A.;Zhang, L.;Yen, C.-J.;Chan, P.C.;Chakrabandhu, S.;Ma, B.B.Y.;Tanasanvimon, S.;Lee, V.H.F.;Lou, P.-J.;Li, Z.;Spira, A.I.;Sukari, A.;Guigay, J.;McCune, S.;Gonzalez-Maffe, J.;Szpakowski, Szpakowski S.;Yao, Yao Y.;Liang, H.;Mataraza, J.;Sechaud, R.;Manenti, L.;Lim, D.W.-T. |
| 國立成功大學 |
2021 |
Clinical and immunologic responses to a B-Cell epitope vaccine in patients with HER2/neu-overexpressing advanced gastric cancer—results from phase Ib trial IMU.ACS.001
|
Wiedermann, U.;Garner-Spitzer, E.;Chao, Y.;Maglakelidze, Maglakelidze M.;Bulat, I.;Dechaphunkul, A.;Arpornwirat, W.;Charoentum, Charoentum C.;Yen, C.-J.;Yau, T.C.;Tanasanvimon, S.;Maneechavakajorn, J.;Sookprasert, A.;Bai, L.-Y.;Chou, W.-C.;Ungtrakul, T.;Drinic, M.;Tobias, J.;Zielinski, C.C.;Chong, L.;Ede, N.J.;Marino, Marino M.T.;Good, A.J. |
Showing items 1-8 of 8 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
